Weekly Digest – January 2025 Weekly Digest – January 2025 30 Dec 2024: ADC Therapeutics announces completion of enrollment of Phase 3 confirmatory clinical trial of ZYNLONTA® in combination with rituximab in 2L+ DLBCL ADC Therapeutics has completed enrollment in […]
Weekly Digest – January 2025 Weekly Digest – January 2025 02 Jan 2025: Innovent enters into exclusive global license agreement with Roche for novel DLL3 Antibody Drug Conjugate Innovent Biologics has entered into a collaboration and exclusive license agreement with […]
Weekly Digest – January 2025 Weekly Digest – January 2025 29 Dec 2024: IDEAYA Biosciences enters exclusive license with Hengrui Pharma for SHR-4849, a novel Phase 1 DLL3 Topo-I-payload ADC targeting SCLC and NET solid tumors IDEAYA Biosciences has entered […]
Weekly Digest – January 2025 Weekly Digest – January 2025 30 Dec 2024: Duality Biologics announces B7H4 ADC milestone achievement and license exercise by BeiGene BeiGene has exercised its exclusive option to the B7-H4 ADC DB1312/BG-C9074 from Duality Biologics, gaining […]
Weekly Digest – January 2025 Weekly Digest – January 2025 29 Dec 2024: Vincerx Pharma enters into a binding term sheet for a strategic merger with Oqory Vincerx Pharma has entered into a binding term sheet for a proposed merger […]
Weekly Digest – December 2024 Weekly Digest – December 2024 27 Dec 2024: DATROWAY® approved in Japan as the first TROP-2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer Daiichi Sankyo’s DATROWAY® […]
